Phaseline

Companies › Oils4Cure

Oils4Cure: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YCJ-01 Full Spectrum Cannabis Extract
Full spectrum cannabis extract
–Phase 3Tuberous Sclerosis Complex (TSC)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07403266YCJ-01 Full Spectrum Cannabis ExtractPhase 3Tuberous Sclerosis Complex (TSC)OtherJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Neuraptive Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.